Jate Samathivathanachai ’01 joined Mammoth Biosciences as Senior Vice President of Finance in February 2025. Mammoth is a Berkeley-affiliated biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop potential long-term curative therapies for patients with life-threatening and debilitating diseases.
Jate Samathivathanachai
March 26, 2025
Share this article
Related Articles
Reading Roundup: Planet Nine, UC and Trump, the Woolly Mammoth
The Sad Last Days of the Woolly Mammoth Hoping to shed light on the woolly mammoth’s decline, UC Berkeley bioinformatics researcher Montgomery Slatkin and a colleague compared the genomes of two of the hairy giants and found that they were mutational hot messes in their last days, with trouble finding where to pee and translucent satin coats that may have looked cool at parties but […]
CRISPR Will Change the World. Here’s What’s Already In the Works
From diagnostics to warfare, a sampling of how gene-editing is being used to rewrite the world’s DNA. In October, UC Berkeley professor Jennifer Doudna shared the Nobel Prize in chemistry for the discovery of CRISPR/Cas9, a gene-slicing tool that can be programmed to make precise edits to DNA. Since its discovery, CRISPR has captured the […]
Lemon or LeMans
If the UC system is like the auto industry, will Janet Napolitano be its Taiichi Ohno or its Rick Wagoner? That’s the question Professor Michael O’Hare left hanging off the end of his open letter to the new UC President-designate yesterday. At over 1,500 words, the Goldman School prof’s long and severe overview of the state […]
Our Partners
